A Phase II Study of the Combination of Avastin [bevacizumab] and Erlotinib in Patients with Unresectable Hepatocellular Carcinoma.

Trial Profile

A Phase II Study of the Combination of Avastin [bevacizumab] and Erlotinib in Patients with Unresectable Hepatocellular Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Dec 2011 Actual patient number is 62 according to ClinicalTrials.gov.
    • 09 Dec 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
    • 09 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top